- Home
- ESRT vs MNKD Comparison
ESRT vs MNKD Comparison
Compare ESRT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- MNKD
- Stock Information
- Founded
- ESRT 2011
- MNKD 1991
- Country
- ESRT United States
- MNKD United States
- Employees
- ESRT N/A
- MNKD N/A
- Industry
- ESRT Real Estate Investment Trusts
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- MNKD Health Care
- Exchange
- ESRT Nasdaq
- MNKD Nasdaq
- Market Cap
- ESRT 1.8B
- MNKD 1.8B
- IPO Year
- ESRT 2013
- MNKD 2004
- Fundamental
- Price
- ESRT $10.60
- MNKD $6.80
- Analyst Decision
- ESRT Hold
- MNKD Strong Buy
- Analyst Count
- ESRT 3
- MNKD 5
- Target Price
- ESRT $10.67
- MNKD $8.40
- AVG Volume (30 Days)
- ESRT 1.2M
- MNKD 2.9M
- Earning Date
- ESRT 10-21-2024
- MNKD 11-07-2024
- Dividend Yield
- ESRT 1.32%
- MNKD N/A
- EPS Growth
- ESRT N/A
- MNKD N/A
- EPS
- ESRT 0.27
- MNKD 0.08
- Revenue
- ESRT $763,203,000.00
- MNKD $267,200,000.00
- Revenue This Year
- ESRT N/A
- MNKD $46.83
- Revenue Next Year
- ESRT $2.20
- MNKD $14.40
- P/E Ratio
- ESRT $38.80
- MNKD $85.77
- Revenue Growth
- ESRT 4.84
- MNKD 51.35
- 52 Week Low
- ESRT $8.39
- MNKD $3.17
- 52 Week High
- ESRT $11.62
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- ESRT 41.98
- MNKD 47.15
- Support Level
- ESRT $10.76
- MNKD $6.61
- Resistance Level
- ESRT $11.01
- MNKD $7.44
- Average True Range (ATR)
- ESRT 0.24
- MNKD 0.35
- MACD
- ESRT -0.03
- MNKD -0.05
- Stochastic Oscillator
- ESRT 19.14
- MNKD 18.63
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.